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Occupancyf HIV-1 neutralization may assist rational vaccine design. Here, we compared
antibody neutralization against the JR-FL primary isolate and trimer binding afﬁnities judged by native PAGE.
Monovalent Fab-trimer binding and neutralization showed a direct quantitative relationship, implying that
neutralization begins as each trimer is occupied by one antibody. At saturation, three Fab or soluble CD4
molecules engaged each trimer. In contrast, a maximum of one soluble CD4 molecule bound to functional SIV
trimers with a truncated a gp41 tail. Remarkably, soluble CD4 was found to trigger dramatic enhancement of
this virus. Unlike Fabs, a quantitative correlation between JR-FL trimer binding and neutralization was
unclear for some, but not all IgGs, as neutralization was markedly increased, but trimer afﬁnity was largely
unchanged. In addition, only one molecule of certain gp41-speciﬁc IgGs appeared to be able to bind each
trimer. We discuss the implications of these ﬁndings in weighing the relative contributions of size,
multivalent binding and other possible effects of IgGs to explain their increased potency.
© 2008 Elsevier Inc. All rights reserved.Introduction
Antibodies (Ab) neutralize viruses by binding surface structures,
thereby blocking infection (Burton et al., 2001; Parren et al., 1998). For
human immunodeﬁciency virus type 1 (HIV-1), neutralization occurs
by occupation of functional gp120/gp41 envelope glycoprotein (Env)
trimers (Fouts et al., 1997; Parren and Burton, 2001; Poignard et al.,
1996). Abs can also recognize non-functional forms of Env present on
HIV-1 particle surfaces. In this case, Ab binding does not result in
neutralization (Herrera et al., 2003; Moore et al., 2006; Nyambi et al.,
1998; Poignard et al., 2003).
The few monoclonal antibodies (mAbs) reported to date capable of
broad and potent neutralization of HIV-1 primary isolates include
IgG1b12 (directed to an epitope overlapping the CD4 binding site of50 North Torrey Pines Road, La
l rights reserved.gp120) (Burton et al., 1994), 2G12 (directed to high mannose carbohy-
drate epitopeof gp120) (Scanlan et al., 2003), 2F5, Z13 and4E10 (directed
to adjacent epitopes at the C-terminal ectodomain of gp41) (Muster et al.,
1993; Zwick et al., 2001; Nelson et al., 2007). Neutralization can occur by
various mechanisms. IgG1b12 blocks attachment to the primary CD4
receptor on cells, 2G12blocks coreceptor binding (Binleyet al., 2006) and
gp41 mAbs neutralize a fusion intermediate complexed with both CD4
and coreceptor (Binley et al., 2003; Crooks et al., 2005; Frey et al., 2008).
MAbs directed to the V3 loop and CD4-induced epitopes show
intermittent activity, usually at quite high concentrations (Binley et al.,
2004; Labrijn et al., 2003; Xiang et al., 2002).
Three molecules of neutralizing Ab (nAb) are thought to bind to
trimers at saturation. In contrast, non-neutralizing epitopes are buried
by Env inter-subunit associations within trimers interactions and are
therefore only exposed on non-functional components such as gp120
(Bou-Habib et al., 1994; Schonning et al., 1999; Yang et al., 2005a).
Interestingly, one report showed that only one molecule of soluble CD4
(sCD4) binds to SIV gp140 trimers, suggesting an exception to 3:1
trimer-ligand stoichiometry (Kim et al., 2001). However, another report
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stoichiometry to native SIV trimers remains unclear.
Many groups have attempted to understand the quantitative aspects
of trimer binding and neutralization (Fouts et al., 1997; Klasse and
Sattentau, 2002; Kwong et al., 2002; McInerney et al., 1997; Ou et al.,
2006; Parren et al., 1998; Salzwedel et al., 2000; Sattentau and Moore,
1995; Schonninget al.,1999; Spenlehaueret al., 2001; Yanget al., 2005a,b;
Klasse, 2007; Yang et al., 2006b). Recurring questions are; how many
subunits need to beoccupied toneutralize each trimer?Howmany spikes
per particle need to be occupied bymAbs to neutralize the virus? And the
effect of mechanism and Ab speciﬁcity. Many of these questions remain
unresolved.
A variety of techniques have provided insights into the process of
neutralization. Some groups have captured inhibitor- and receptor-
bound trimers (Frey et al., 2008; Furuta et al., 1998; Mkrtchyan et al.,
2005). Others have visualized ligand binding by gel ﬁltration, co-
immunoprecipitation, analytical ultracentrifugation and isothermal
titration calorimetry (Kimet al., 2001; Kwonget al., 2002; Pancera et al.,
2005; Srivastava et al., 2007, 2002). Crystallography has revealed the
structures of nAbs, alone and in complex with Env proteins and
peptides (Calarese et al., 2003; Kwong et al., 1998; Ofek et al., 2004;
Saphire et al., 2001; Zhou et al., 2007). However, functional trimers have
not been investigated by any of these methods to date, owing to the
difﬁculties in generating sufﬁcient quantities, puriﬁcation, and instabil-
ity. Recently, however, native trimer structures (Zanetti et al., 2006; Zhu
et al., 2006) and trimer complexes with neutralizing ligands (Bennett
et al., 2007) have been visualized by cryoelectron tomography.
The outcome of neutralization assays can be dramatically inﬂu-
enced by the conditions of the assay. For example, target cells with a
low CCR5 surface density may extend the lifetime of the CD4-liganded
trimers, allowing certain Abs to inhibit more effectively (Binley et al.,
2004; Choudhry et al., 2006). A post-CD4 binding neutralization
format can similarly enhance the effect of some Abs (Crooks et al.,
2005; Decker et al., 2005). The size of the ligand may also affect its
potency. In some cases, smaller inhibitors can better access cryptic
epitopes, as exempliﬁed by mAb X5 that detectably neutralizes as a
monovalent Fab, but not as an IgG (Labrijn et al., 2003). On the other
hand, IgG1b12 neutralizes much more effectively than its monovalent
Fab counterpart (Burton et al., 1994). High valency versions of sCD4
fused with IgG constant domains also neutralize more effectively than
sCD4 monomer (Arthos et al., 2002; Bennett et al., 2007; Trkola et al.,
1995). A dodecameric CD4 protein was reported to cross-link trimers
on separate particles, perhaps also “inactivating” any other trimers
that happen to be close to the apposing membranes of the cross-
linked particles, as they would not be capable of engaging target cell
surfaces (Bennett et al., 2007). Even more surprising was the
observation of increased particle "rupturing" by this dodecameric
CD4 protein (Bennett et al., 2007). Overall, however, the relative
contributions of valency, afﬁnity, avidity, physical bulk or other factors
to the increased neutralizing activities of IgGs and other multivalent
molecules remain largely unresolved.
In this article, we investigate the quantitative relationship of trimer
binding and neutralization. We also examine the effects of ligand
speciﬁcity, size and valency on trimer binding and neutralization. We
also look at mAb binding to sCD4-trimer complexes, the stoichiometry
of sCD4 binding to HIV and SIV trimers and the consequences of 1:1 or
3:1 sCD4:trimer stoichiometry on infection.
Results
Behavior of trimers from various isolates in native PAGE
In previous reports, we described native PAGE as a method to
directly visualize ligand binding to HIV particle-derived functional
trimers (Crooks et al., 2007; Crooks et al., 2005; Moore et al., 2006). In
addition to trimers, we found various forms of non-functional Env onHIV-1 surfaces, including gp120/gp41 monomer and gp41 stumps. To
establish any patterns that might relate to Env phenotype, we initially
compared our JR-FL prototype to Envs from various other isolates in
BN-PAGE. We chose gp160ΔCT versions of Env analogous to that used
for JR-FL (Moore et al., 2006), because expression and processing into
gp120/gp41 is more efﬁcient. Previous comparisons of live inactivated
virus preparations and pseudoviruses, including those with tail
truncations and “SOS” disulﬁde mutations in native PAGE and virus
capture assays suggest that the infectious pseudovirions exactly
mirror the behavior of live primary isolates (Binley et al., 2003; Crooks
et al., 2005; Moore et al., 2006; Poignard et al., 2003). Furthermore,
truncated JR-FL trimers were found to retain comparable function and
neutralization resistance to their full-length counterparts (Crooks
et al., 2007; Crooks et al., 2005; Moore et al., 2006).
A comparison of trimers from clades A, B and C and SIVmac239 and
SIVmac316 pseudoviruses, and inactivated HIV-1 MN and ADA
preparations by BN-PAGE is shown in Fig. 1. Many of the clade B and
all of the C isolates are derived from published virus panels developed
for standardized measurement of neutralization activity (Li et al.,
2005; Li et al., 2006). In some cases, trimers formed sharp bands
similar to JR-FL (e.g. KNH1144 ec1 (Brown et al., 2005), REJO, TRJO,
WITO, 6101, DU156 and ZM214). Three neutralization-sensitive
trimers (MN, 1196, and SF162) were rather diffuse, perhaps indicating
more “open” trimer structures. On the other hand, HXB2 trimers were
somewhat sharper, like JR-FL. Some trimers were efﬁciently expressed
like JR-FLSOS (e.g. KNH1144 ec1, 3988, TRJO, ZM214, and AC10), while
others were poorly expressed or absent (e.g. 1196, ZM249, DU422,
ZM233, 6535, and SF162). In some cases, the lack of a clear trimer band
is mirrored by low infectivity of the pseudoviruses (e.g. isolates
ZM249, ZM233, and 6535 each give infectious virus counts of
b60,000 relative light units; R.L.U.). However, others (1196, DU422,
and SF162) gave rather high infectious counts (N150,000 R.L.U.). This
may be because 1) the small quantity of trimers present are highly
fusogenic (possibly SF162), 2) the trimers are particularly diffuse and
therefore difﬁcult to visualize (1196, DU422), or 3) trimers are
unusually labile and fall apart in native PAGE (1196, DU422).
Some Envs exhibited more than one oligomeric band, for example,
the trimer doublet of 3988 or the multiple bands of ZM135, DU172,
ZM197 and ZM109 (Fig.1A). Further analysis in reducing SDS-PAGE gels
indicated the presence of uncleaved Env. Uncleaved Env can exist in
various multimeric forms, possibly accounting for these additional
oligomer bands (Moore et al., 2006). A disproportionate fraction of
clade C Envs harbored multiple oligomeric bands. The clade B trimers
from the virus panel (Li et al., 2005) on the other hand were quite
consistent in their expression and mobility, perhaps reﬂecting their
uniform neutralization resistance. The additional bands seen below the
monomer in Fig. 1 are gp41 trimers and monomers, as identiﬁed
previously (Moore et al., 2006).
Interestingly, Env from the neutralization-resistant SIVmac239
isolate and its sensitive derivative, SIVmac316 resolved in two distinct
oligomer forms (Fig. 1B). The lower band appears to be a trimer, while
the upper band is estimated to be ~800 kDa, larger than any band
observed for the HIV-1 isolates. We hypothesize that this might
represent dimers of trimers, analogous to the dimers of gp120-GCN4
trimers reported previously (Pancera et al., 2005). Alternatively, the
band might represent trimers complexed with an undeﬁned mem-
brane protein. Reducing SDS-PAGE indicated negligible uncleaved
gp120/gp41 precursor (not shown), ruling out this as a possible
explanation. The sensitive SIVmac316 bore proportionately more of
the larger Env form compared to SIVmac239. The SIVmac316 trimers
were also slightly slower moving than the SIVmac239 counterpart
(estimated at 420 kDa versus 386 kDa), suggesting that the latter,
neutralization-resistant trimers may be more compact. Env derived
from live inactivated SIVmac239 particles behaved identically to its
VLP counterpart in BN-PAGE, indicating that the patterns observed are
not a artifact of pseudovirions (Fig. 1B).
Fig. 1. Behavior of native Env from various clade A, B and C HIV-1 viruses and SIVmac239 and SIVmac316 in native PAGE. Gp160ΔCT Env trimers derived from concentrated
pseudovirion stocks were examined in BN-PAGE with reference to our JR-FL gp160ΔCT prototype. JR-FL gp160ΔCT trimers and monomers and gp41 trimers and monomers (Moore
et al., 2006) are indicated by cartoons. In part A, and the middle section of part B, blots were probed with a cocktail of HIV+ donor plasmas. In the left and right panels of part B, blots
were probed with either the HIV-1 gp120 mAb or SIV mAb cocktails, as described in materials and methods. Asterisks (⁎) denote Envs derived from a published clade B virus panel
(Li et al., 2005) and a sharp sign (#) denotes Envs from a published clade C virus panel (Li et al., 2006).
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We next investigated the binding of a panel of Fabs to JR-FL trimers
over a range of concentrations. As we planned to determine trimer
binding afﬁnity by depletion of uncomplexed trimer in the presence of
mAb, we ﬁrst established the relationship of Env loaded in BN-PAGE
and its detection in Western blot using densitometry. Gp120 was
titrated in BN-PAGE in Fig. 2 (upper panel) and the relationship
between densitometry and amount loaded is plotted in the lower
panel. Clearly, there is a direct relationship, suggesting that our
intention to measure trimer-Ab afﬁnity bymeasuring trimer depletion
in BN-PAGE should yield reasonable estimates. Interestingly, the BN-Fig. 2. Relationship of band density and gp120 quantity in BN-PAGE. Graded
concentrations of JR-FL gp120 were loaded in BN-PAGE. Band densities were calculated
and plotted against the microgram quantity of gp120.PAGE revealed a fraction of gp120 dimers, as reported by others
(Center et al., 2000).
In BN-PAGE, we found that neutralizing Fabs (2G12, b12, 2F5, Z13
WT, and Z13 e1) and sCD4 were able to shift JR-FL trimers (Fig. 3).
Speciﬁcity was conﬁrmed using trimers with point mutations at
residues 295 and 368 that selectively eliminate 2G12 or b12 binding,
respectively (E. Crooks and J. Binley, in preparation). We determined
afﬁnities by measuring depletion of unliganded trimer and did not
factor liganded complexes into the estimates, as the detection Ab
cocktail may react differently with trimers in complex with test mAbs.
The afﬁnities of each neutralizing Fab for trimers and monomers were
similar, indicating little or no energy barrier for trimer versus
monomer binding. In contrast, most non-neutralizing Fabs bound to
monomer, but their epitopes were conformationally occluded on
trimers (b6, AH48, HIVIG, T2, T3, P7 in Fig. 3 and Table 1), conﬁrming
the exclusive relationship of trimer binding and neutralization. Fab X5
did not bind effectively to gp120/gp41 monomers and may therefore
recognize other forms of Env, such as monomeric gp120 or receptor-
bound forms of Env.
Incremental occupation of trimers by 1, 2 and 3 molecules of Fab
2G12 was observed over a broad concentration range (Fig. 3A).
Binding was detectable at b0.3 µg/ml, but did not become fully
saturated even at 100 µg/ml (Fig. 3A). The intensity of the bands
became brighter with increasing concentration, presumably because
2G12 remains bound to trimers after Western blotting, leading to
increased detection sensitivity. Similar progressive binding was
observed for gp41 Fabs. The pattern for Z13 WT was particularly
clear (Fig. 3H). In contrast, 4-domain sCD4 (4D-sCD4) saturated at a
precise concentration. This may indicate triggering of a structural
change at a threshold concentration, exposing all 3 CD4 binding sites
(Fig. 3D). Similar results were obtained with 2-domain sCD4 (2D-
sCD4) (Table 1). For comparative purposes, we examined the effect of
sCD4 on ADA and MN trimers (Fig. 3L). ADA trimers were shifted in a
similar manner to those of JR-FL. However, sCD4 binding led to a large
Fig. 3. Quantitative Ligand Binding to JR-FL trimers. Graded concentrations of Fabs or 4D-sCD4 were incubated with JR-FL SOS-VLPs Env trimers were then resolved by BN-PAGE. In
one experiment (panel J), VLPs were washed to remove unbound Fab before native PAGE. Neutralizing IC50s and estimated trimer IC50s are indicated. Cartoons depict gp120/gp41
trimers andmonomers and bound ligands. Black circles depict 4D-sCD4 and shaded circles depict Fab. The molecular weights of trimers andmonomers were previously estimated as
420 kDa and 140 kDa (Moore et al., 2006). The masses of trimers complexed with saturating concentrations of neutralizing Fabs were estimated as follows: 2G12 (780 kDa), b12
(614 kDa), 4D-sCD4 (620 kDa), 2F5 (493 kDa), Z13 WT (551 kDa) and Z13e1 (533 kDa). In the case of the gp41 Fabs, the complexes with three Fabs were unclear, so the molecular
weights given are estimated of trimers with two Fabs bound. Panel L shows the effects of saturating (20 µg/ml) 2D- and 4D-sCD4 on live inactivated MN and ADA preparations.
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Table 1
Summary of the neutralizing titers of various ligands and their afﬁnities for JR-FL Env
trimers and monomers
ICS50 concentration in μg/ml(nM)
Epitope Ligand Monomer
shift
Trimer shift Neutralization
CD4bs b12 Fab 2(40) 2 (40) 1 (20)
b12 IgG N30 (200) 2 (13) 0.05 (0.3)
b6 Fab 15 (300) N50 (N1000) N50 (N1000)
Mannose cluster 2G12 Fab 0.2 (2) 0.3 (3) 0.5 (5)
2G12 IgG 1 (7) 1 (7) 0.21 (1.4)
2G12 IgG+4D-sCD4 N.D. N.D. 0.08 (0.5)
V3 loop AH48 Fab 3 (60) N50 (N1000) N50 (N1000)
AH48 Fab+4D-sCD4 0.08 (1.6) 0.3 (6) 0.001 (0.02)
Cluster I gp41 T2 Fab N50 (N1000) N50 (N1000) N50 (N1000)
Cluster II gp41 T3 Fab N50 (N1000) N50 (N1000) N50 (N1000)
CD4 2D-sCD4 0.8 (32) 0.8 (32) 0.5 (20)
4D-sC4 0.3 (6) 0.3 (6) 0.8 (16)
CD4-IgG2 N30 (180) 0.5 (3) 0.015 (0.09)
gp41 MPER 2F5 Fab 0.3 (6) 0.3 (6) 5 (100)
2F5 Fab⁎ 15 (300)⁎ 15 (300)⁎ 5 (100)
2F5 Fab+4D-sCD4⁎ 7 (140)⁎ 7 (140)⁎ N.D.
2F5 IgG 10 (66) 10 (66) 0.2 (1.4)
2F5 IgG+4D-sCD4 N.D. N.D. 0.02 (0.14)
4E10 IgG 5 (33) 5 (33) 2 (14)
Z13 WT Fab 2 (40) 5 (100) 45 (900)
Z13 e1 Fab 0.3 (6) 1 (20) 26 (520)
Z13 e1 Fab⁎ 60 (1200)⁎ 60 (1200)⁎ 26 (520)
Z13 e1 IgG 10 (66) 30 (200) 26 (173)
CD4i X5 Fab N50 (N1000) N50 (N1000) N50 (N1000)
X5 Fab+4D-sCD4 0.06 (1.2) 0.3 (6) 0.0009 (0.018)
gp41 prehairpin T-20 N.D. N.D. 0.1 (25)
T-20+4D-sCD4 N.D. N.D. 0.04 (10)
C1 conformational P7 Fab 2 (410) N50 (N1000) N50 (N1000)
IC50s are given in µg/ml and the corresponding titers in nM are given in parentheses,
assuming molecular weights of ligands as follows: Fabs 50 kDa, IgG 150 kDa, CD4-IgG2
170 kDa, T-20 peptide 4 kDa. In some cases, titers are given in the presence of a ﬁxed
concentration of sCD4 (5 µg/ml). Post-CD4 neutralization by mAbs AH48, 2F5 and X5
was measured on CCR5 only-expressing cell lines (Crooks et al., 2005). IC50s are
representative of several repeat assays. An asterisk (⁎) denotes experiments in which
trimer binding was measured in a format where unbound ligand was washed away
prior to detergent treatment of VLPs. N.D.=not done.
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consistent with sCD4-induced gp120 shedding.
A ladder of partially and fully liganded trimers was not evident for
Fab b12 as it was for the other neutralizing Fabs (Fig. 3B). This may be
due to its enzymatic production from IgG1b12 by papain digestion,
yielding a somewhat heterogeneous mixture of Fab products of
slightly differing sizes, contrasting the more consistent expression by
phagemid vector used for the other Fabs. It follows that binding of this
Fab b12 mixture to trimers results in the rather diffuse complexes
observed. At saturation, the estimated molecular weight of the largest
trimer-Fab complexes suggests that 3 Fab molecules bind in each case.
Saturating concentrations of 2G12 shifted trimers to an estimated
molecular weight of ~780 kDa, dramatically larger than with Fab b12
and 4D-sCD4, where saturated complexes were ~620 kDa (compare
Figs. 3A, B and D). This is consistent with the inherent dimeric nature
of 2G12 Fabs, resulting from a unique domain exchange conformation
(Calarese et al., 2003), making it approximately twice the size of the
other Fabs and 4D-sCD4.
Comparing afﬁnity with neutralization potency revealed a generally
good agreement for gp120 ligands, suggesting a simple quantitative
relationship (Fig. 3 and Table 1). In contrast, gp41 Fabs 2F5, Z13WTand
Z13 e1 bound to trimersmore potently than they neutralized (Figs. 3G–I
and Table 1). A much closer correlation of neutralization and trimer
binding IC50s existed, however,whenwemeasured Z13 e1 trimer shifts
in a format where unbound Fab was washed away prior to detergent
treatment of VLPs in preparation for BN-PAGE (compare Figs. 3I and J
and Table 1). Similar resultswere obtainedwith other gp41membrane-proximal ectodomain region (MPER)-speciﬁc mAbs 2F5 and Z13 WT
(Table 1 and not shown). In contrast, gp120 ligands bound equivalently,
regardless of an additional wash step. This suggests that there may be
constraints on MPER exposure on native spikes that may be released
after trimers are liberated by detergent.
Effects of sCD4 binding on trimer epitope exposure
Entry inhibitors may be categorized as CD4-inhibiting, CD4-
induced, or CD4 impartial. We attempted to visualize these scenarios
in BN-PAGE. Soluble CD4 complexing with trimers greatly enhanced
the binding of V3 Fab AH48 (Fig. 4A), consistent with its drastically
increased neutralizing activity in a post-CD4 format (Table 1). Similar
results were observed with CD4i mAbs (Table 1 and ref. (Crooks et al.,
2005)). The molecular weight of the trimer fully complexed with 4D-
sCD4 and AH48 (Fig. 4A)was estimated as ~780 kDa.With reference to
the molecular weight of 4D-sCD4 liganded trimers of ~620 kDa, this
suggests that 3 copies of Fab AH48 bind per sCD4-saturated trimer.
Interestingly, the stoichiometry of X5 binding to CD4-trimer com-
plexes differed from AH48 (BN-PAGE shown in Fig. 3B of ref. (Crooks
et al., 2005)). The molecular weight of Fab X5 complexes with 4D-
sCD4 and trimer were estimated at ~653 kDa, suggesting a 1:1
stoichiometry of X5: sCD4/trimer binding. This result was further
supported using different sized ligands: 2D-sCD4 gave a shift to
~515 kDa (suggesting 3:1 CD4:trimer stoichiometry), to which the
addition of a single chain Fv X5 fragment only increased the complex
molecular weight to 548 kDa (Crooks et al., 2005). This suggests that
there may be steric constraints on CD4i mAb-trimer binding. Given
the similarity of the CD4i epitope and the CCR5 binding site, (Trkola
et al., 1996), it will be of interest to investigate whether trimer/sCD4:
CCR5 binding is also limited to a 1:1 stoichiometry.
In contrast to Fab AH48, Fab b12 competed with sCD4 for trimer
binding (Fig. 4B). Addition of increasing concentrations of b12 in the
presence of a ﬁxed 4D-sCD4 concentration caused a decrease in the
size of the complexed trimer, as b12 replaced sCD4's positions on each
gp120 component. The mobility of 4D-sCD4 complexed trimers was
somewhat slower than b12-trimer complexes, despite the similar
molecular weights of these two ligands (~50 kDa) (Fig. 3 compare
parts B and D). This may be because 4D-sCD4 is an extended
polyprotein of four IgG subdomains, whereas the Fab is a more
compact heterodimer of two IgG subdomains. In a similar experiment,
titration of Fab b12 in the presence of a ﬁxed 2D-sCD4 concentration
resulted in liganded trimers of increasingmobility, as b12 replaced the
smaller 2D-sCD4's positions on each gp120 subunit (Fig. 4B).
4D-sCD4 binding resulted in a slight enhancement Fab 2F5 afﬁnity
(Fig. 4C and Table 1), consistent with a mild increase in neutralization
potency in the post-CD4 format (Crooks et al., 2005). The molecular
weight of trimer+sCD4+2F5 at close to saturation was estimated as
795 kDa, consistent with a 3:1 stoichiometry of 2F5 binding to the
trimer:sCD4 complexes. A similar slight increase in afﬁnity was also
observed for 2G12 (not shown) (Binley et al., 2006).
The low mass of peptides based on the C-terminal helix of gp41
wouldmake their binding impossible tovisualize inBN-PAGE.However,
C34-Ig, a molecule consisting of a C34 peptide fused to a human Fc
fragment (Si et al., 2004) was able to perceptibly bind to trimers,
especially in the presence of 4D-sCD4 (Fig. 4D). Consistent with this
observation, the activity of a related peptide, T-20, was also slightly
induced in the presence of sCD4 (Table 1) (Binleyet al., 2003; Yuan et al.,
2004). Insufﬁcient material precluded an estimate of C34-Ig's neutra-
lizing IC50, but it was clearly greater than 5 µg/ml (N83 nM). Thus, C34-
Ig appears to be somewhat less potent than the T-20 peptide (Table 1).
The magnitude of shifts in the absence (~27 kDa) or presence of sCD4
(~52 kDa) was consistent with binding of only one molecule of C43-Ig
dimer (~60 kDa) or monomer (~30 kDa) per trimer. It is unclear
whether this is due to the limited access of this bulkier molecule to its
target or its weaker afﬁnity.
Fig. 4. Ligand binding to JR-FL in the presence of sCD4. The binding of various ligands to JR-FL SOS-VLP trimers was determined in the presence or absence of 2D- or 4D-sCD4
(5 µg/ml). A) Fab AH48. B) Fab b12. C) Fab 2F5. D) C34-Ig. In the case of 2F5, unbound Fabwas washed away prior to loading samples in BN-PAGE, but in all other cases, ligand was
left in. A ﬁnal concentration of 40 µg/ml (666 nM) C34-Ig was added to VLPs. Cartoons indicate liganded and unliganded trimers. Black circles depict 4D-sCD4, white circles
depict 2D-sCD4, shaded circles depict Fab andC34-Ig. Inpart A, the size of the 4D-sCD4+AH48 saturated trimer (far right lane)was estimated as 780 kDa. Inpart C, the size of trimer+sCD4
+2F5 complexes at near saturation (right lane) was estimated as 795 kDa. In part D, the sizes of complexed trimers were estimated as: lane 2 (trimer+C34-Ig) 447 kDa; lane 3 (trimer+4D-
sCD4) 620 kDa; lane 4 (trimer+4D-sCD4+C34-Ig) 672 kDa.
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Previous studies have variously described of 3:1 or 1:1 sCD4-
trimer binding stoichiometry for soluble gp140 versions of SIV trimers
(Earl et al., 1992; Kim et al., 2001). We reinvestigated this question
here using functional SIV trimers. Neutralization-sensitive SIVmac316
trimers bound potently to 4D-sCD4, with an IC50 of ~1 µg/ml
(~20 nM) (Fig. 5A). Although 4D-sCD4-trimer complexes did not
resolve clearly, complexes with the putative trimer dimer were
observed (right 3 lanes of Fig. 5A). The high mass and diffuse nature of
these complexes made it difﬁcult to accurately assign a molecular
weight and therefore to determine how many CD4 molecules were
bound. Soluble CD4 bound to SIVmac316 monomers and trimers with
similar afﬁnity, suggesting that trimers do not impose constraints on
sCD4 binding, as we observed with JR-FL (compare Figs. 3D and 5A).
Soluble CD4 bound to monomers from the neutralization-resistant
SIVmac239 isolate with a high afﬁnity (Fig. 5B). However, 4D-sCD4 did
not bind SIVmac239 trimers at concentrations up to 200 µg/ml (4 µM)
(Fig. 5B). This suggests that inter-subunit associations within
SIVmac239 trimers conformationally disfavor sCD4 binding. Further
investigation using a very high concentration of 2D-sCD4 (2 mg/ml;
80 µM) revealed a modest SIVmac239 trimer shift, compared to the
marked shift induced in JR-FL trimers (Fig. 5C). The estimated
molecular weights of trimer-CD4 complexes were ~443 kDa and
~510 kDa, respectively (assuming unliganded trimers are each
~420 kDa), consistent with binding of one ~25 kDa sCD4 molecule
per SIV trimer and 3 per JR-FL trimer.
The relationship between IgG-trimer binding and neutralization
We next investigated the relationship between neutralization titer
and trimer afﬁnity using IgG versions of mAbs in a similar manner to
the Fab analysis in Fig. 3. One challenge in using whole IgGs for BN-PAGE is in Western blot detection. Anti-Fc conjugate can cross-react
with any residual free IgG that is loaded in the gel. Preliminary studies
revealed that uncomplexed IgG resolves as a smear, and reduces the
quality of Western blots. To eliminate this problem, we included a
wash step before detergent treatment of VLPs and BN-PAGE, to
remove any unbound IgG.
We ﬁrst compared IgG binding of JR-FL and ADA trimers using ﬁxed
high concentrations of IgGs. The neutralizing IgGs bound to both
trimers, as evidenced by a depletion of unliganded trimer, coupled in
most cases with the appearance of high molecular weight complexes
or smears (Fig. 6A). IgG binding exhibited several idiosyncrasies
compared to the more straightforward Fab binding (compare Figs. 3
and 6). First, IgG-trimer complexes with CD4-IgG2, IgG1b12, and 2F5
largely formed unresolved smears, in contrast to the clear shift
observed for the equivalent Fab-trimer complexes. Second, a band of
near identical size to unliganded trimer was observed in the presence
of 2G12 IgG. This is not surprising, considering that Fab 2G12-
monomer complexes moved slightly ahead of unliganded trimers in
Fig. 3A and factoring the somewhat increased size of the IgG version.
Bands of similar size to trimers were also observed for IgG1b12 and
2G12 binding to inactivated ADA particles (Fig. 6A, right panel). Third,
unliganded monomer was observed with JR-FL VLPs incubated with
high concentrations of certain IgGs, in particular CD4-IgG2 and
IgG1b12 (Fig. 6A, and compare right lanes of Figs. 6B and C to those
of Figs. 6D–G). The poor resolution of ADAmonomers made it difﬁcult
to determine whether this phenomenon also applied here. We noted
however, that non- or weakly neutralizing IgGs b6, 39F and LE311
bound and depleted monomer quite effectively, suggesting that this
may be a phenomenon associated only with certain neutralizing IgGs
(Fig. 6A, middle panel). These non-neutralizing IgGs revealed yet
another idiosyncrasy in the form of a faint apparent shifted trimer
band that was not accompanied by a measurable depletion of
unliganded trimer. This was particularly prominent for the V3 mAbs.
Fig. 5. Soluble CD4 afﬁnity and stoichiometry for SIV trimers. Graded concentrations of 4D-sCD4 were mixed with A) SIVmac316 or B) SIVmac239 Env trimers in BN-PAGE.
C) Saturating concentrations (2 mg/ml; 80 µM) of 2D-sCD4 were mixed with JR-FL and SIVmac239 Env trimers in BN-PAGE. Cartoons indicate bound and unbound forms of Env.
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mAb concentrations.We are now investigating the possibility that this
band stems from traces of uncleaved trimer, or, more interestingly
from an alternative trimer isoform (Yuan et al., 2006).
We next titrated the IgGs in BN-PAGE. Despite neutralizingHIV-1 JR-
FL approximately 100-foldmore potently (on a nMscale, inTable 1), the
increase in trimer afﬁnities of IgG1b12 and CD4-IgG2 compared to their
monovalent Fab and 4D-sCD4 counterparts were relatively small (2–10
fold; compare Fig. 3B, D and Figs. 6B, C; and Table 1). Similarly, 2F5 IgG
neutralizedmore than 70-foldmore potently but its trimer afﬁnity was
only 5 fold higher than its Fab counterpart (Table 1). In contrast, 2G12
4E10 and Z13 e1 IgG IgG-trimer afﬁnities matched their neutralizing
IC50s (Figs. 6D and F). The activity of 2G12 IgGwas in fact similar to that
of the equivalent Fab (Table 1). Trimer afﬁnity estimation was
particularly complicated for 2G12 because liganded monomer almost
co-migrated with unliganded trimer. In estimating the 2G12 trimer
afﬁnity, we therefore took into account the density of this monomer
+2G12 band at saturation, as well as the appearance of trimer
complexes. Our afﬁnity estimate closely matches that of 2G12 Fab
(Fig. 3A and Table 1). This was expected, considering that 2G12 IgG is
monovalent, so the Fab and IgG differ bymass but not valency (Calarese
et al., 2003).
Interestingly, 4E10 and Z13e1 both gave a visible IgG-trimer band
(Figs. 6F and G), similar to the multiple bands observed for 2G12, but
distinct from the rather more diffuse or completely absent trimer
complexes with IgG1b12, CD4-IgG2 and 2F5 IgG. The estimated
molecular weights of these bands were estimated as 626 kDa and
720 kDa, respectively. This appears to suggest trimer complexes with a
one or two IgGs respectively. However, the calculation of molecular
weights using IgGs may be a slight overestimate in contrast to the
simpler Fab ligands. This is exempliﬁed by the fact that the prominent
shifted trimer band observed in lane 5 of Fig. 6D (2G12 at 1 µg/ml)
gave amolecular weight of 696 kDa. The banding pattern in this ﬁgure,
with two further higher molecular weight 2G12-trimer complexes
appearing at higher concentrations (Fig. 6D, right lanes), makes it clear
that despite the large estimated size (~276 kDa larger than
uncomplexed trimer), this is in fact trimer complexed with a single
2G12 IgG. By similar reasoning, we suggest that the IgG-trimer bands
of 4E10 IgG and Z13e1 IgG also reﬂect a single IgGmolecule bound to a
trimer.
One possible explanation for the disagreement in trimer binding
afﬁnities and neutralization potencies for CD4-IgG2, IgG1b12, and 2F5
IgG may be that we are underestimating trimer afﬁnities due to a
technical difﬁculty similar to that for 2G12, i.e. as IgG-complexed
gp120/gp41 monomer co-migrates with unliganded trimer (Figs. 6B–E), the apparent trimer afﬁnity may be reduced artiﬁcially. However,
arguing against this possibility, unlike 2G12, the trimer-sized band at
saturating concentrations of these IgGs is virtually absent. Never-
theless, to address this problem, we generated F(ab')2 fragments from
IgGs by pepsin digestion. These smaller fragments should eliminate
possible band co-migration, while retaining the valency of the
parent IgGs. Pepsin digestion created functional F(ab')2 fragments of
b12 and 4E10, asmeasured by ELISA (not shown). These bound to JR-FL
trimers at precisely the same concentrations as the whole IgGs (not
shown), suggesting that our afﬁnity estimates are accurate.
Different consequences of 1:1 and 1:3 sCD4-trimer binding stoichiometry
for infection
We next investigated the effects of CD4-based molecules of
different sizes and valencies (2D-sCD4, 4D-sCD4 and CD4-IgG2) on
the infection of HIV-1 and SIV bearing trimers that have differing CD4
binding stoichiometries (Fig. 7). We used cell lines expressing both
CD4 and CCR5 receptors (Fig. 7, left panels) or CCR5 only (Fig. 7, right
panels). The concentrations of the 3 CD4-based species are given in
nM to allow direct comparisons, eliminating the effect of their
differing molecular weights. The corresponding trimer binding IC50s
in nM, where known, are given in Table 1 for JR-FL and in Fig. 5 for the
two SIV isolates.
In the absence of sCD4, SIVmac316 infection was detectable,
consistent with its CD4-independent phenotype (Fig. 7D), in contrast
to the CD4-dependent SIVmac239 virus (Fig. 7E) (Johnson et al., 2003;
Puffer et al., 2002). Surprisingly, 2D- or 4D-sCD4 binding to SIV
gp160ΔCT trimers dramatically enhanced infection of CD4/CCR5 cells
(Figs. 7A and B). This suggests that one molecule of sCD4 binds each
trimer, resulting in a conformational change that increases exposure of
the CCR5 binding site (as illustrated by the cartoons adjacent to Figs. 7A
and B). Though we were unable to ascertain the stoichiometry of sCD4
binding to SIVmac316 in native PAGE (Fig. 5), the similar enhancing
effects of sCD4 on these two viruses implies that the 1:1 sCD4:trimer
stoichiometryapplies to both. The enhancement steadily increased over
a broad concentration range, beginning atmuch lower concentrations of
sCD4 for SIVmac316 (~0.1 nM) than for SIVmac239 (~100nM) (compare
Figs. 7A and B), consistent with the large sCD4 afﬁnity differences
observed in BN-PAGE (Fig. 5). The sCD4 concentration required for half
maximal enhancement of SIVmac316 infection and trimer binding
appeared to correspond (~20 nM) (compare Figs. 5 and 7A). A similar
consistency between enhancement and trimer binding appears likely
for SIVmac239, though we have not determined the exact trimer
binding IC50, which is between 4 and 80 µM (Figs. 5 and 7B). In general,
Fig. 6. Binding of whole IgG mAbs to JR-FL trimers. A) Various IgGs (at 30 µg/ml) were incubated with JR-FL SOS-VLPs or ADA inactivated particles and resolved by BN-PAGE. B)-G)
Increasing concentrations of IgG1b12, CD4-IgG2, 2G12, 2F5, 4E10, or Z13e1 were mixed with JR-FL SOS-VLPs. Unbound IgG was removed by a wash with PBS. Cartoons indicate
liganded and unliganded trimers. Though the ligands are in the form of IgGs, for convenience, they are depicted as two shaded circles. N.D. = not done. Neutralizing IC50s and
estimated trimer IC50s are indicated, where available. The trimer complexes with one 2G12 IgGmolecule (part D, lane 5) were estimated at 696 kDa, those of 4E10 IgG and Z13e1 IgG
were estimated as 626 kDa and 720 kDa, respectively.
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than the larger 4D-sCD4 (Figs. 7A andB). Thus, trimers complexed to the
bulkier 4D-sCD4 have a somewhat sterically diminished CCR5 binding
capacity compared to those complexed with the smaller CD4 molecule.
The inﬂuence of size appears to be further supported by the
observation that CD4-IgG2 inhibited rather than enhanced SIV infection
(Figs. 7A and B). Although CD4-IgG2 binding induces a conformational
change in trimers, exposing CCR5 binding sites, its bulk appears to
obscure CCR5 engagement, resulting in a net interfering effect (as
illustrated in the cartoons associated with Figs. 7A and B).
When infection was assayed on cells expressing only CCR5 (no
CD4), sCD4-induced enhancement was again observed (Figs. 7D and
E). The degree of enhancement induced by 2D-sCD4 remained only
slightly higher than 4D-CD4, contrasting with the more dramatic
difference observed on CD4/CCR5 cells. CD4-IgG2 also moderately
enhanced SIVmac316 and SIVmac239 infection, in contrast to its
effect when infection was assayed on CD4/CCR5 cells (Fig. 7, compare
parts A and B with parts D and E). Thus, in this low baseline infectionscenario, CD4-IgG2-induced exposure of coreceptor binding sites was
more important than its tendency to inhibit CCR5-engagement due
to its bulk. In fact, all the CD4-based molecules ultimately lead to
almost identical infection levels of both cell types and it is the
baseline infection levels that differ (Fig. 7, compare parts A and B to
parts D and E).
In contrast to their effects on SIV, CD4-based ligands all inhibited
JR-FL infection of CD4/CCR5 target cells (Fig. 7C), presumably by
blocking receptor and/or coreceptor binding. Concentrations of sCD4
that would be expected to lead to partial trimer occupation (~10 nM)
did not enhance infection as they did for SIV. This may be because the
remaining open CD4 binding sites on partially liganded JR-FL trimers
can also interact with cellular CD4, leading to net interference (Fig. 7C,
see cartoons). This scenario is not possible for SIV, because amaximum
of only one sCD4 molecule can bind to each trimer (Figs. 7A and B).
In stark contrast to the effect on CD4/CCR5 cells, when CCR5 only
cells were used to measure infection, we observed a remarkable
enhancement of JR-FL by all CD4 ligands, peaking at concentrations
Fig. 7. Effect of CD4 binding stoichiometry on HIV-1 and SIV infection. 2D-sCD4, 4D-sCD4 and CD4-IgG2 were incubated with SIVmac316 (A, D), SIVmac239 (B, E) or JR-FL (C, F)
gp160ΔCT viruses, and infection in relative light units (R.L.U.) wasmeasured on CF2 target cells bearing both CD4 and CCR5 (left panels) or CCR5 only (right panels). Baseline infection
of CCR5-expressing targets with no sCD4 (not shown) was identical to that at the lowest sCD4 concentrations shown. The effects of CD4-based ligands on SIV and HIV-1 infection are
illustrated by cartoons. The levels of infection in each cartoon scenario is depicted by + signs. Soluble CD4 (2D- or 4D-) is depicted as 4 black circles, and CD4-IgG2 is depicted as a
series of black circles in an IgG conformation.
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(compare Fig. 7C and F). The peaks correspond to concentrations
sufﬁcient partial CD4 binding, presumably causing a global conforma-
tional change that enhances trimer binding to cellular CCR5, most
likely by the remaining open subunits of the trimer (see cartoons inFig. 7F). When the trimer becomes fully saturated, the enhancement
wanes, as sCD4 appears to interfere with cellular CCR5 binding by the
same trimer subunit. The enhancement may occur on CCR5 only cells
because non-productive interference between cellular and soluble
forms of CD4 is eliminated (compare cartoons in Figs. 7C and F). As
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types and the differences observed in Fig. 7F versus Fig. 7C lies in the
lower baseline infection level that reveals the activating effect of sCD4.
Also as observed with the SIV viruses (Figs. 7A and C), 2D-sCD4
enhanced JR-FL infection to a somewhat greater extent than 4D-sCD4.
It is interesting to compare the IC50 titers of monovalent and
multivalent CD4 molecules against JR-FL and SIV viruses. As men-
tioned above, the potency of CD4-IgG2 against JR-FL (enhancement or
inhibition, depending on assay format) was much greater than that of
sCD4 (IC50=~0.1 nM versus ~10 nM; Fig. 7C and Table 1). In contrast,
the CD4-IgG2 IC50 against SIVmac316 trimers was exactly the same as
monovalent sCD4 counterparts (compare Figs. 7A and C). SIVmac239
was more potently affected by CD4-IgG2, as for JR-FL (Fig. 7B).
The enhancement of SIV isolates by sCD4 observed here contrasts
with its neutralizing effect against SIV described previously (Pikora,
Wittish, and Desrosiers, 2005; Yuste et al., 2005). The sCD4 IC50
concentrations required were comparable, however: SIVmac239
neutralization by 4D-sCD4 was previously reported to occur at an
IC50 concentration similar to where enhancement occurs in our
experiments (~500 nM; Fig. 7B). One possible explanation for this
discrepancy was our use of truncated rather than full-length gp160
pseudovirions. Indeed, we found that sCD4 neutralized rather than
enhanced equivalent full-length gp160 SIV pseudovirions (not shown),
suggesting that the full-length gp160 allows a 3:1 sCD4: trimer binding
stoichiometry similar to JR-FL.
Discussion
Neutralization and trimer binding as probed by native PAGE
We showed here a direct, quantitative correlation between Fab-
trimer binding and neutralization, regardless of epitope, suggesting
that afﬁnity is a major factor in determining neutralization potency.
Our data are consistent with neutralization beginning when one mAb
binds to each spike (Schonning et al., 1999; Yang et al., 2005a,b) and
complete neutralization is reached when all spikes become saturated.
MPER epitopes were found to be partially occluded in native
trimers embedded in membranes. This constraint was lifted when
trimers were liberated from particles. Similar ﬁndings were reported
in a study that examined the neutralization sensitivities of viruses
with the 2F5 epitope grafted into the SU or TM of MLV Env (Ou et al.,
2006). The decreased sensitivity of the TM graft to neutralization
matches the conformational occlusion we observed, suggesting that
Abs directed to TM might have to overcome binding constraints not
present for SU mAbs (Ou et al., 2006). However, our ﬁndings that
detergent treatment exposes MPER epitopes on trimers appears to
contrast with reports that membranes increase binding of MPER
antibodies to Env proteins captured on the surfaces of proteolipo-
somes and other particles (Grundner et al., 2002; Phogat et al., 2008).
Therefore, the form of Env captured could dictate the inﬂuence of
phospholipid context on MPER Ab binding afﬁnity.
Trimer binding stoichiometry
A report by Kimet al. (2001) showed that only onemolecule of sCD4
bound to uncleaved soluble gp140 SIVmac32H trimers(Kim et al.,
2001). We demonstrated here that this phenotype is preserved in
functional cleaved SIV trimerswith a truncated gp41 tail but not in full-
length trimers. Several explanations were previously proposed to
explain the 1:1 sCD4:trimer stoichiometry (Kim et al., 2001). We can
now rule out inappropriate gp120-gp41 association, since our trimers
are proteolytically mature and functional. The possibility that each
gp120 comprises of a partial CD4 binding site that is only complete
when gp120s are packed in the trimer structure can also be ruled out,
because monomeric forms of SIV Env readily bind to sCD4, suggesting
that 3 binding sites are potentially available in each trimer. Stericconstraints were previously considered an unlikely explanation, since
even the smallest 2D-sCD4 bound only once to SIV gp140 trimers (Kim
et al., 2001). However, if the binding site is close to the trimer axis (Chen
et al., 2005), perhaps only one sCD4 can gain access, regardless of its
size, and therefore a single CD4 molecule occludes the remaining two
sites. This partial exclusion of binding sites is reminiscent of ﬁndings
with HIV-1 gp120 trimers generated by fusion with a C-terminal
oligomerization motif, to which a maximum of only two molecules
were shown to bind (Pancera et al., 2005). As with our SIV trimers,
interactions between the gp120 monomers might restrict sCD4 access.
Interestingly, removal of the V-loops relieved these constraints,
allowing 3 molecules of sCD4 to bind.
Ourdata show that single sCD4binding to trimers activates infection
of CCR5-expressing cells but three sCD4 molecules interfere with
infection (Figs. 7D, E and F). Thus, a single sCD4 molecule can induce a
global structural change in all three gp120/gp41 subunits of trimers. The
exposed coreceptor binding sites can then mediate infection of
coreceptor-expressing cells. In particular, the open subunits of the
trimer that are not bound to sCD4 appear to mediate CCR5 binding, as
indicated by reduced enhancement of JR-FL at saturating sCD4
concentrations when infection is assayed on CCR5 cells (Fig. 7F). This
is consistent with the idea that infection is optimally mediated by
trimers bearing at least two wild type gp120/gp41 subunits, one
responsible for binding CD4 and another for binding CCR5 (Yang et al.,
2006a). Constraints on CCR5 binding are also suggested by our ﬁnding
that only one X5 molecule appears able to bind trimers saturated by
sCD4 (Crooks et al., 2005).
In contrast to JR-FL, SIV enhancement was observed even at very
high sCD4 concentrations, as binding is saturated at a 1:1 stoichio-
metry, eliminating the possibility of coreceptor binding interference
by further sCD4 molecules binding to the trimer. Soluble CD4: SIV
trimer afﬁnities measured by BN-PAGE corresponded well with the
concentrations required to enhance infection (Figs. 5 and 7), just as
Fab:trimer afﬁnities corresponded to neutralization IC50s for JR-FL.
Soluble CD4 bound SIVmac316 trimers incrementally over a broad
concentration range, only showing signs of saturation at 1000 nM, a 4
orders of magnitude higher concentration than that at which the
enhancement began. Quantities of sCD4 precluded an investigation of
the saturation of SIVmac239 trimers with increasing sCD4. In contrast
to SIVmac316 trimers, JR-FL trimers are insufﬁcient saturated over a
narrow range. This is consistent with a global conformational change
in trimers induced by a single sCD4 molecule binding, leading to the
cooperative binding of other CD4 molecules (Fig. 3D; compare the
effects of 2D-sCD4 in Figs. 7A and C). Clearly, this cooperative CD4
binding is not available for the SIV trimers studied here.
Paradoxically, neutralizing mAbs can occasionally moderately
enhance HIV-1 infection at limiting concentrations (Koch et al.,
2003). It is possible that partial mAb binding induces slight conforma-
tional changes that result in enhanced infection, if the remaining
unoccupied monomers function slightly more effectively than they do
at ground state (albeit to a much lower extent than sCD4). Indeed,
some nAbs are known to induce conformational changes upon binding
to viral proteins (Emini et al., 1983). A study that showed entropic
changes as a result of mAb-Env complexing provides further circum-
stantial evidence of this possibility (Kwong et al., 2002).
Gp41 truncation is a natural adaptation of some SIV isolates to
growth in human T cell lines, with a stop codon appearing at residue
734 (Bonavia et al., 2005; Kodama et al., 1989; Puffer et al., 2004).
SIVmac239 particles harboring this stop codonwere recently analyzed
by cryoelectron tomography, revealing that the majority of spikes
reacted with only one sCD4 molecule, even when sCD4 was added in
great molar excess (K. Roux and P. Zhu, personal communication). This
agrees with the 1:1 trimer:sCD4 stoichiometry we showed here for
SIVmac239 particles with a stop codon at 718, leaving a two amino
acid gp41 tail. However, it appears that not all truncation mutants
show this unexpected CD4 stoichiometry. SIVmac239 particles
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were neutralized rather than enhanced by sCD4, similar to the full-
length SIVmac239 trimer-bearing viruses, rather than our truncation
mutant. Taken together, it appears that 1:1 CD4:trimer stoichiometry
applies only to dramatically truncated SIV Env trimers and it will be
worth investigating graded SIV gp41 tail truncations to determine
where the switch from 3:1 to 1:1 stoichiometry occurs. We speculate
that the 734 truncationmutant found in Tcell culturesmay be selected
on the basis of increased growth capacity. It might be envisaged that
trimers binding a single CD4 molecule rather than 3 leaves coreceptor
binding sites unencumbered for more efﬁcient coreceptor binding and
entry.
It will be interesting to determine whether SIV trimers can also
restrict mAb binding to a 1:1 stoichiometry. Kim et al. (2001) reported
that, in contrast to sCD4, uncleaved SIV gp140 trimers can bind 3 Ab
molecules(Kim et al., 2001). Despite a paucity of neutralizing reagents
reactive with SIVmac239, this point could be investigated using
viruses bearing the more sensitive SIVmac316 trimers. Moreover, it
will be interesting to compare the structures of SIV trimers that
exhibit differing CD4 stoichiometries to understand the basis and
possible implications for infection and neutralization. The very large
SIV oligomeric band observed in BN-PAGE that may be dimers of
trimers (Fig. 5) also clearly warrants further investigation.
Possible explanations for the increased neutralization potency of IgGs
compared to monovalents
The greater neutralization potencies of IgG1b12, CD4-IgG2 and 2F5
IgG compared to their monovalent counterparts might be attributable
to any or all of several unique IgG properties. Size clearly seems to
matter. Increased bulk has been suggested to account for the greater
neutralizing potency of a dodecameric CD4 molecule, D1D2-IgP
(Arthos et al., 2002). In the present study, the contribution of size is
supported by a comparison of 2D- and 4D-sCD4, of which the bulkier
of the two exhibited greater interference (Fig. 7). CD4-IgG2 neutralized
rather than enhanced SIV infection, perhaps further suggesting an
effect of size. The difference is probably not due to increased avidity, as
the IC50 titer would be expected to be lower if more than one CD4-
IgG2 Fab arm is engaged (as for JR-FL, compare Figs. 7A and C). Overall,
increasing size appears to affect magnitude of the effect but not the
titer, i.e. in Fig. 7, increasing size lowers viral infectivity (vertical scale),
but not IC50 (horizontal scale).
Avidity may also inﬂuence neutralization, increasing the potency
of multivalent ligands. This may occur in 3 ways; crosslinking epitopes
on a single spike, crosslinking neighboring spikes on the same particle
or bridging spikes on different particles. It is likely that higher avidity
would increase neutralization titer, shifting curves to the left in Fig. 7,
contrasting the effect of ligand size. CD4-IgG2 had a lower IC50 against
JR-FL, suggesting that it crosslinks more than one gp120 subunit.
We ﬁrst consider the possibility of multivalent binding to a single
spike. It might be envisaged that one IgG Fab arm bound to trimer puts
the other Fab arm in close vicinity of the 2 remaining targets on the
same trimer. IgGs molecules are ﬂexible at their hinge regions,
allowing Fab arm “wag” in 3 dimensions (Burton, 1990; Hanson et al.,
1981; Roux et al., 1997; Zhu et al., 2001). The Fab arms themselves are
also able to rotate about their long axis and considerable ﬂexing can
occur at the elbow between the variable and constant domains. This
could mean that IgGs can contort in conformations allowing simul-
taneous engagement of Fab arms. However, speciﬁcity may exert an
important constraint on the possibility of multivalent binding to a
single spike. While IgGs that bind epitopes near the trimer apex may
be able to crosslink, those that bind radially or laterally to their
epitopes may not, due to the geometric limits of Fab arm ﬂexibility.
Modeling studies suggest that 2G12 may fall into the ﬁrst category,
and IgG1b12, CD4-IgG2, 2F5 and 4E10 fall into the latter (Kwong et al.,
2000; Zhu et al., 2001), though deﬁnitive data are still lacking. 2G12 isan exceptional case since the locked Fabs have no ﬂexibility with
respect to one another, and intra-spike crosslinking therefore appears
to be highly unlikely.
Despite their theoretical inability to bind individual spikes more
than once, IgGs that bind laterally may be able to bridge different
spikes on the same virus. The difﬁculty in observing clear trimer-IgG
complexes in BN-PAGE in many cases comparable to the clear trimer-
Fab complexes (compare Figs. 3 and 6) could imply that both Fab arms
engage different spikes, forming higher order complexes that are
difﬁcult to resolve. However, we can not rule out the possibility that
these smears stem simply from inherent IgG ﬂexibility, with the only
counter-argument being our ﬁnding of clear trimer-Z13e1 IgG and
4E10 IgG complexes (Fig. 6F and G). Dodecameric D1D2-IgP has been
shown to crosslink trimers on SIV particles that bare ~70–79 spikes
(Bennett et al., 2007). Others have suggested that CD4-IgG2 is capable
of intravirion trimer crosslinking (Zhu et al., 2001). The trimer
afﬁnities of IgG1b12, CD4-IgG2, and 2F5 IgG we measured in BN-
PAGE appear to support this possibility. Multivalent binding to a single
spike would be expected to increase the trimer afﬁnity compared to
the equivalent Fabs. If, on the other hand, increased IgG avidity
emerges from crosslinking separate spikes, binding each only once,
the afﬁnity on a per trimer basis measured against individual spikes in
BN-PAGE might be expected to match that of the respective Fabs, as
observed (Figs. 3, 6 and Table 1). In light of the lower spike density of
our JR-FL VLPs (~27/particle (Moore et al., 2006)), this model would
require that trimers are either clustered or mobile in the lipid bilayer
(Sougrat et al., 2007; Zhu et al., 2006). The cytoplasmic tail truncated
trimers used here may make the possibility of mobility more likely. It
may therefore be worth comparing these viruses to those bearing full-
length gp160 trimers that might be properly anchored and therefore
immobile.
IgGs may also be able to bridge spikes on separate particles
(Bennett et al., 2007). This would be expected to be less dependent of
speciﬁcity, and more on sufﬁcient particle concentrations to bring
neighboring viruses into proximity. In theory, the number of spikes
inactivated compared to the number of spikes actually bound by
ligand may be increased if the spikes on closely apposed surfaces of
crosslinked particles are rendered incapable of accessing the target
cell surface and mediating entry (Bennett et al., 2007). A potential
caveat for inter-particle crosslinking is that non-neutralizing Abs can
bind to non-functional forms of Env such as gp41 stumps present on
particle surfaces (Poignard et al., 2003) and might therefore
conceivably be able to crosslink particles. However, these mAbs do
not neutralize, perhaps because in practice the density of non-
functional Env is too low for this effect to be signiﬁcant.
Overall, it is not yet clearwhich of themodes ofmultivalent binding
is more important in neutralization, if any, and this may vary,
depending on the speciﬁc features of the ligand. The balance of data
in our study suggests that inter-spike crosslinking is predominant. The
only apparent contradiction comes from an analysis of the effects of
CD4-IgG2 and sCD4 against truncated SIVmac316 trimers. The SIV
particles bear a greater spike density than JR-FL (~73 versus ~27),
perhaps increasing the likelihood of inter-spike crosslinking. However,
the observed lack of an increased CD4-IgG2 neutralization titer
compared to sCD4 suggests that CD4-IgG2 binds only once and inter-
spike crosslinking does not occur, or at least is not important for
neutralization of this virus. By default, this might be taken to suggest
that intra-spike crosslinking (not available for the SIVmutant) explains
the increased titer of CD4-IgG2 against JR-FL (Fig. 7). One counter-
argument is that the different positioningof the single CD4 binding site
on SIV trimers may limit spike crosslinking so that neutralization is
reduced to a simple 1:1 trimer binding scenario. In contrast, the
orientation of the 3 CD4 binding sites on JR-FL trimers renders them
available for inter-spike crosslinking. However, close inspection of
SIVmac239 neutralization (Fig. 7B), shows that CD4-IgG2 exerts an
effect at a signiﬁcantly lower IC50 (~1 nM) than sCD4, as for JR-FL.
375E.T. Crooks et al. / Virology 377 (2008) 364–378Collectively then, our data indicate that crosslinking is important for
neutralization of primary isolates, but may be relatively unimportant
for highly sensitive viruses like SIVmac316.
The observation that the 4E10 IgG and Z13 e1 IgG trimer afﬁnities
matched its neutralization potencies was unexpected, considering the
differences observed for IgG1b12, CD4-IgG2, and 2F5 IgG. In fact, in this
respect, Z13 e1 and 4E10's behavior better reﬂects that of the mono-
valent ligands. A similarity between 4E10 IgG, Z13e1 IgG and
monovalent Fabs is further supported by the observation that they
form clear complexes with trimers in BN-PAGE (Fig. 6), unlike the
smears observed for IgG1b12, CD4-IgG2, and 2F5 IgG. Interestingly,
molecular weight estimates indicated that only a single 4E10 or Z13e1
IgGmolecule binds to trimers at saturation, in contrast to Fab Z13e1, of
which 3molecules can bind. Thismight indicate that steric constraints
limit access of the larger IgGs to their membrane-proximal epitopes.
Overall, it is difﬁcult at this stage to determine whether the lack of a
marked increase in Z13e1 IgG neutralization compared to its Fab
counterpart stems from limited access to its epitope or an inability to
crosslink spikes, or indeed both.
A recent study reported that dodecameric D1D2-IgP induces
particle “rupturing” (Bennett et al., 2007). Conceivably, this could be
the result of the separation of previously crosslinked particles, leading
to removal of a “plug” of Env-complex from one partner. Perhaps
related to this notion, our consistent observation of signiﬁcant
amounts of unliganded gp120/gp41 monomer in native PAGE at
saturating concentrations of IgG1b12 and CD4-IgG2 was unexpected
(right lanes in Figs. 6B and C). Since trimers are fully liganded at this
concentration, this free monomer is unlikely to indicate low mAb
afﬁnity, especially considering that saturating concentrations of
monovalent Fab b12 and sCD4 did not leave unliganded monomer
(Figs. 3B and D), as did a non-neutralizing IgG, b6 to a similar epitope
(Fig. 6A). It might therefore be proposed that IgG binding destabilizes
trimers, leading to free monomers and permanent spike inactivation.
This provides another possible explanation for the difﬁculty in
visualizing IgG-trimer complexes in Fig. 6. Since the SOS mutant we
used here prevents gp120 shedding, the putative dissociation most
likely occurs at the trimer axis, leading to gp120/gp41 monomers
(Moore et al., 2006). Given at this is likely to be a permanent
neutralizing effect it may be worth investigating the cumulative
activities of these IgGs in native PAGE and neutralization assays over
time. Clearly, more work will be required to determine exactly how
neutralizing IgGs interact with trimers and how this affects
neutralization.
Materials and methods
MAbs, HIVIG, C34-Ig and sCD4
Anti-HIV-1 gp120monoclonal antibodies (mAbs) included b12 and
b6, directed to epitopes that overlap the CD4 binding site (CD4bs)
(Burton et al., 1994); 2G12, directed to a unique glycan-dependent
epitope on gp120 (Sanders et al., 2002; Scanlan et al., 2002); X5,
directed to a CD4-inducible (CD4i) epitope (Darbha et al., 2004;
Labrijn et al., 2003); 447D, 39F, LE311 and AH48, directed to the V3
loop (Crooks et al., 2005; Schulke et al., 2002); P7, directed to a
conformational epitope of the C1 region of gp120 (Ditzel et al., 1997).
Anti-gp41 mAbs 2F5, Z13 WT (Zwick et al., 2001; Muster et al., 1993)
and its derivative Z13e1 are directed to the membrane-proximal
ectodomain region (Nelson et al., 2007). T2 and T3 are directed to
clusters 1 and 2 of gp41, respectively (Binley et al., 1996). Anti-SIV
mAbs included 5B11, 7D3, 171C2, and 8C7, 1.7A, and 3.10A (Cole et al.,
2001; Edinger et al., 2000). A plasmid expressing the chimeric fusion
of the C34 peptide and the Fc portion of IgG (C34-Ig) that recognizes
the putative prehairpin gp41 fusion intermediate was expressed in
293T cells and puriﬁed over protein G (Si et al., 2004). HIVIG was
puriﬁed IgG derived from pools of HIV-infected donor plasma. Solubleforms of CD4 (sCD4) included one consisting of all 4 ectodomains (4D-
sCD4) and another consisting of domains 1 and 2 only (2D-sCD4).
Fab fragments were in most cases expressed in bacteria, using the
pComb3 vector (Barbas et al., 1993). Fab b12 was prepared by papain
digestion of IgG according to manufacturer's protocols (Pierce,
Rickford, IL). IgGs were digested into monovalent F(ab')2 fragments
using immobilized pepsin, respectively, also according to manufac-
turer's protocols (Pierce, Rickford, IL).
MAbs b12, 2G12, and 2F5 are broadly and potently neutralizing
(Binley et al., 2004); mAb Z13 and its improved derivative are weak,
but broadly neutralizing; mAb X5 neutralizes primary isolates of HIV-
1 in the presence of sCD4 (Crooks et al., 2005; Moulard et al., 2002);
the V3 loop-speciﬁc Abs neutralize a subset of primary isolates (Binley
et al., 2004); HIVIG, T2, T3, b6 and P7 do not neutralize primary HIV-1
isolates.
MAbs 2G12 and 2F5 were provided by Dr. H. Katinger (Polymun
Scientiﬁc Inc., Vienna, Austria). Two and four domain sCD4 and CD4-
IgG2 (Jacobson et al., 2004) were provided by Progenics Pharmaceu-
ticals Inc (Tarrytown, NY). MAb 447D was provided by Dr. Susan Zolla-
Pazner (NYU). HIVIG was provided by John Mascola (NIH VRC). The
C34-Ig plasmid was provided by Drs. Joe Sodroski and Zhihai Si.
Viruses and plasmids
Pseudoviruses were produced by transient transfection of 293T
cells with the plasmids pNL-LucR-E- and an Env expressing plasmid,
pCAGGS to express JR-FL gp160ΔCT SOS, as described previously
(Moore et al., 2006). Gp160ΔCT WT Env clones of SIVmac239,
SIVmac316, KNH1144 ec1, 3988, 1196, REJO, TRJO, 92US715, THRO,
RHPA, QHO515, CAAN, ZM214, ZM135, ZM249, DU422 and DU172
were constructed in pCAGGS in an analogous manner to JR-FL (Binley
et al., 2003). The SIV Envs were cloned with a stop codon at residue
718, leaving a 2 amino acid gp41 tail. Env source plasmids were
provided by Welkin Johnson (Harvard), David Monteﬁori (Duke
University), Francine McCutchan and the NIH AIDS Repository.
Concentrated preparations of inactivated HIV-1 MN and ADA and
SIVmac239 viruses were provided by Drs. Larry Arthur and Jeff Lifson.
The SIVmac239 virus has been grown in SupT1 cells and is known to
have a stop codon at residue 734.
Neutralization assays
Pseudovirus neutralization assays were performed as described
previously (Binley et al., 2003; Crooks et al., 2005). Brieﬂy, in standard
assays, virus was incubated for 1 h with inhibitors, before adding the
mixture to CF2.CD4.CCR5 target cells for 2 h, followed by a wash and a
further 2 day incubation. In post-CD4 neutralization assays, virus was
incubated with a ﬁxed concentration of 5 µg/ml 4D-sCD4 and graded
concentrations of mAb. Subsequently, infection was assayed on CF2
cells bearing high concentrations of surface CCR5. All assays involved a
15 min 1000 rpm spinoculation step with the remainder of the
infection in an incubator at 37 °C.
Native PAGE
BN-PAGE was performed as described previously (Crooks et al.,
2007; Crooks et al., 2005; Moore et al., 2006). Brieﬂy, concentrated
VLPs or inactivated HIV particles were incubated with or without mAb
or sCD4 for 5 min at RT. The concentration of sCD4 and/or Fab or IgG
used in trimer shift experiments was recorded as that in the ﬁnal
mixture with VLPs. In experiments using IgG, VLPs pellets were
washedwith 1ml PBS to remove possible interference by unbound IgG
upon anti-Fc detection in Western blot. The mixture was then gently
solubilized for 5 min in 2× solubilization buffer (1% Triton X-100/1%
NP40 in 1 mM EDTA) in 1.5 M aminocaproic acid to liberate Env. An
equal volume of 2× sample buffer (100 mM MOPS, 100 mM Tris–HCl,
376 E.T. Crooks et al. / Virology 377 (2008) 364–378pH 7.7, 40 % glycerol, 0.1 % Coomassie blue) was then added prior to
loading onto a 4–12% Bis-Tris NuPAGE gel (Invitrogen). Ferritin (Sigma)
was used as a size standard. Samples were electrophoresed at 4 °C for
3 h at 100 V with 50 mMMOPS/50 mM Tris pH 7.7 containing 0.002 %
Coomassie blue as cathode buffer and the same buffer without
Coomassie blue as the anode buffer. The gel was then blotted onto
PVDF, destained, and probed using mAbs b12, 2G12, E51, 39F, 2F5 and
4E10 (anti-HIV mAb cocktail), a pool of plasmas from HIV+ donors
(Crooks et al., 2007) or 5B11, 7D3, 171C2, 8C7, 1.7A and 3.10A (anti-SIV
cocktail) (Cole et al., 2001; Edinger et al., 2000). Goat anti-human Fc
alkaline phosphatase conjugates were then used to detect the primary
Abs (Jackson). Trimer binding was determined by depletion of
unliganded trimer in Western blots. Band densities were determined
using UN-SCAN-IT software (Silk Scientiﬁc). The IC50 of trimer shifts
were determined by plotting these data versus ligand concentration.
Molecular weights were also estimated using this software according
to software guidelines, assigning JR-FL or SIV gp160ΔCT trimers and
monomers with molecular weights of 420 and 140, respectively, as
markers for deﬁning the masses of other bands.
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